This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Embecta Corp. (EMBC) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
Embecta Corp. (EMBC) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Company News for May 15, 2023
by Zacks Equity Research
Companies in The News Are: IAG, SLF, NWSA, EMBC.
Embecta Corp. (EMBC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Embecta Corp. (EMBC) closed the most recent trading day at $28.52, moving -1.82% from the previous trading session.
Embecta (EMBC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
Embecta Corp. (EMBC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Embecta Corp. (EMBC) closed at $27.36 in the latest trading session, marking a -1.12% move from the prior day.
Embecta Corp. (EMBC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Embecta Corp. (EMBC) closed at $29.46, marking a +0.58% move from the previous day.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
New Strong Buy Stocks for April 4th
by Zacks Equity Research
EMBC, BNPQY, OLLI, CASY and JRVR have been added to the Zacks Rank #1 (Strong Buy) List on April 4, 2023.
Best Momentum Stocks to Buy for March 30th
by Zacks Equity Research
HQI, EMBC and DTC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 30, 2023.
New Strong Buy Stocks for March 30th
by Zacks Equity Research
HQI, EMBC, DTC, GSBD and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on March 30, 2023.
Here's Why You Should Retain Elevance (ELV) in Your Portfolio
by Zacks Equity Research
Strong local presence, improving top line, membership hike and significant new contracts in its government business poise Elevance Health (ELV) well for growth.
3 Medical Services Stocks to Buy Amid Industry Challenges
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most. However, staffing shortages may disrupt the trend.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Best Momentum Stocks to Buy for February 24th
by Zacks Equity Research
PLL, TXT and EMBC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 24, 2023.
New Strong Buy Stocks for February 24th
by Zacks Equity Research
PLL, TXT, EMBC, DE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on February 24, 2023.
Best Value Stocks to Buy for February 24th
by Zacks Equity Research
DTEGY, TXT and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 24, 2023.
New Strong Buy Stocks for February 21st
by Zacks Equity Research
EMBC, INSP, REPYY, BZLFY and CVI have been added to the Zacks Rank #1 (Strong Buy) List on February 21, 2023.